Methods for treating prostate cancer with LHRH antagonists

A method for inhibiting agonist-induced hormone surge caused by LHRH agonist therapy in a subject in need of LHRH agonist therapy;

• comprising:
• administering to the subject an LHRH antagonist in a sustained-release formulation;
• and
• administering to the subject an LHRH agonist;
• such that the agonist-induced hormone surge is inhibited in the subject.

A method for inhibiting agonist-induced hormone surge caused by LHRH agonist therapy in a subject in need of LHRH agonist therapy, comprising:

• administering to the subject an LHRH antagonist for a period of at least about 14 days at a dose of about 15-300 .mu.g/kg/day;
• and
• administering to the subject an LHRH agonist,
• such that the agonist-induced hormone surge is inhibited in the subject.

A method for inhibiting agonist-induced hormone surge caused by LHRH agonist therapy in a subject in need of LHRH agonist therapy, comprising:

• administering to the subject an LHRH antagonist having the following structure:
• Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, N.-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH;
• and
• administering to the subject an LHRH agonist;
• such that the agonist-induced hormone surge is inhibited in the subject.

A method for inhibiting agonist-induced hormone surge caused by LHRH agonist therapy in a subject in need of LHRH agonist therapy, comprising:

• administering to the subject an LHRH antagonist having the following structure:
• Ac-D-Nal.sup.1, 4-Cl-D-Phe.sup.2, D-Pal.sup.3, N-Me-Tyr.sup.5, D-Asn.sup.6, Lys(iPr).sup.8, D-Ala.sup.10 -LHRH at a dosage of about 15-300 .mu.g/kg/day in a sustained-release formulation for a period of at least about 14 days;
• and
• administering to the subject an LHRH agonist;
• such that the agonist-induced hormone surge is inhibited in the subject.

A method for inhibiting "acute-on-chronic" agonist-induced hormone surge caused by LHRH agonist therapy in a subject in need of LHRH agonist therapy, comprising:

• administering to the subject an LHRH agonist at regular intervals;
• and
• co-administering to the subject an LHRH antagonist with the LHRH agonist during each interval;
• such that the "acute-on-chronic" agonist-induced hormone surge is inhibited in the subject.